DB05887ExperimentalSmall molecule
TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in...
- Mechanism
- Curator reviewed
TAFA-93 has distinct mechanism of action than calcineurin inhibitors such as ISA247, Isotechnika’s lead drug. It has the pontential to be administered as a complementary therapy along with ISA247 in the prevention of organ rejection after transplantation.
- Primary indication
- Investigated for use/treatment in transplant (rejection).Curator reviewed
- Code names
- TAFA-93
Resolves to
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with TAFA-93, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account